PPP2CB

Across TCGA pan-cancer cohorts, PPP2CB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PPP2CB data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PPP2CB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PPP2CB expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where PPP2CB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.654	0.268	<.001	47	view →
UCEC	DFS	Median	II,III,IV	0.923	0.503	.006	20	view →
HNSC	DFS	Median	II,III,IV	0.750	0.536	.008	13	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.844	.040	3	view →
GBM	DFS	Median	All	0.564	0.770	.024	3	view →
LUAD	OS	Quartile	II,III,IV	0.477	0.896	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PPP2CB–PDAC (OS)

Open the PDAC breakdown →